Monashee Investment Management LLC Acquires Shares of 160,336 Immatics N.V. $IMTX

Monashee Investment Management LLC acquired a new stake in shares of Immatics N.V. (NASDAQ:IMTX) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 160,336 shares of the company’s stock, valued at approximately $1,684,000.

Other hedge funds have also added to or reduced their stakes in the company. Bank of America Corp DE increased its position in Immatics by 166.0% during the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock valued at $25,000 after purchasing an additional 2,231 shares during the period. Insigneo Advisory Services LLC purchased a new position in Immatics during the 3rd quarter valued at $103,000. Fox Run Management L.L.C. purchased a new position in Immatics during the 4th quarter valued at $129,000. Engineers Gate Manager LP purchased a new position in Immatics during the 2nd quarter valued at $124,000. Finally, Verition Fund Management LLC purchased a new position in Immatics during the 3rd quarter valued at $385,000. 64.41% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have issued reports on IMTX. TD Cowen began coverage on shares of Immatics in a research report on Tuesday, April 28th. They set a “buy” rating on the stock. Chardan Capital restated a “buy” rating and set a $25.00 target price on shares of Immatics in a report on Tuesday, May 19th. Mizuho set a $25.00 target price on shares of Immatics in a report on Thursday, February 19th. Weiss Ratings restated a “sell (d)” rating on shares of Immatics in a report on Tuesday. Finally, Jefferies Financial Group assumed coverage on shares of Immatics in a report on Monday, March 16th. They set a “buy” rating and a $18.00 target price on the stock. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $20.80.

Immatics Trading Up 2.1%

Shares of NASDAQ:IMTX opened at $9.06 on Friday. The stock has a fifty day simple moving average of $10.80 and a two-hundred day simple moving average of $10.26. Immatics N.V. has a 12-month low of $5.05 and a 12-month high of $12.41. The stock has a market capitalization of $1.21 billion, a price-to-earnings ratio of -4.55 and a beta of 1.30.

Immatics (NASDAQ:IMTX) last released its earnings results on Tuesday, May 12th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.08). Immatics had a negative return on equity of 47.36% and a negative net margin of 572.35%.The company had revenue of $8.81 million during the quarter, compared to analysts’ expectations of $9.79 million. As a group, equities research analysts predict that Immatics N.V. will post -1.67 EPS for the current year.

About Immatics

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.